microtubule associated protein 10Genealiases: KIAA1383 · MTR120
Q-omics provides the consensus-scored MAP10 profile across patient tissues and cancer cell-line models. MAP10 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MAP10 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, MAP10 RNA expression shows 18,446 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and THCA as cancer lineages where MAP10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAP10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAP10 survival associations across molecular data types. MAP10 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAP10 RNA expression–survival associations across cancer types. High MAP10 expression shows unfavorable associations in UVM, LGG and STAD, but favorable associations in MESO, SKCM and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MAP10 RNA expression.
This table summarizes MAP10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MAP10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAP10 shows lower tumor expression in THCA, UCEC, KICH and COAD and higher tumor expression in LUAD and LUSC. The THCA box plot shows higher MAP10 RNA expression in normal versus tumor tissue (log2 FC = −1.280, t-test p < 0.001).
This table shows molecular features associated with MAP10 in patient tissues and cancer cell lines. In patient samples, MAP10 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MAP10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
